Baxter International Inc. (NYSE:BAX) has a beta of 0.68, a 12-month trailing P/E ratio of 40.49, and a growth ratio of 3.63. The stock’s Relative Strength Index (RSI) is 42.91, with weekly volatility at 1.69% and ATR at 1.33. The BAX stock’s 52-week price range has touched low of $74.79 and a $91.58 high. Its shares traded higher over the last trading session, gaining 0.55% on 05/14/21. The shares fell to a low of $83.505 before closing at $83.86. Intraday shares traded counted 2.19 million, which was 15.77% higher than its 30-day average trading volume of 2.60M. BAX’s previous close was $83.40 while the outstanding shares total 505.00M.
Investors have identified the Medical Instruments & Supplies company Baxter International Inc. as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $41.94 billion, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.
Baxter International Inc. (BAX) Fundamentals that are to be considered.
When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. For BAX, the company has in raw cash 3.18 billion on their books with 407.0 million currently as liabilities. How the trend is over time is what investors should be concerned about. The company has a healthy balance sheet as their debt profile has been on an incline. In terms of their assets, the company currently has 7.86 billion total, with 3.19 billion as their total liabilities.
Having a look at the company’s valuation, the company is expected to record 4.04 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on BAX sounds very interesting.
Is the stock of BAX attractive?
In related news, SVP, President, APAC, Frye Andrew sold 10,999 shares of the company’s stock in a transaction that recorded on Apr 12. The sale was performed at an average price of 84.79, for a total value of 932,605. As the sale deal closes, the Director, HELLMAN PETER S now sold 4,990 shares of the company’s stock, valued at 421,954. Also, Director, STROUCKEN ALBERT P L sold 4,990 shares of the company’s stock in a deal that was recorded on Apr 05. The shares were price at an average price of 84.56 per share, with a total market value of 421,954. Following this completion of acquisition, the SVP and General Counsel, Martin Sean now holds 47,001 shares of the company’s stock, valued at 3,697,794. In the last 6 months, insiders have changed their ownership in shares of company stock by 0.20%.
10 out of 18 analysts covering the stock have rated it a Buy, while 7 have maintained a Hold recommendation on Baxter International Inc.. 0 analysts has assigned a Sell rating on the BAX stock. The 12-month mean consensus price target for the company’s shares has been set at $93.50.